A detailed history of Ubs Group Ag transactions in Ptc Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 165,071 shares of PTCT stock, worth $6.48 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
165,071
Previous 136,761 20.7%
Holding current value
$6.48 Million
Previous $4.18 Million 46.44%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$30.39 - $37.66 $860,340 - $1.07 Million
28,310 Added 20.7%
165,071 $6.12 Million
Q2 2024

Aug 13, 2024

SELL
$24.69 - $40.12 $2.19 Million - $3.56 Million
-88,699 Reduced 39.34%
136,761 $4.18 Million
Q1 2024

May 13, 2024

SELL
$24.15 - $31.95 $1.53 Million - $2.02 Million
-63,288 Reduced 21.92%
225,460 $6.56 Million
Q4 2023

Feb 09, 2024

BUY
$18.07 - $29.37 $3.81 Million - $6.19 Million
210,883 Added 270.83%
288,748 $7.96 Million
Q3 2023

Nov 09, 2023

SELL
$22.41 - $41.99 $317,908 - $595,670
-14,186 Reduced 15.41%
77,865 $1.74 Million
Q2 2023

Aug 11, 2023

BUY
$40.4 - $59.1 $615,251 - $900,033
15,229 Added 19.82%
92,051 $3.74 Million
Q1 2023

May 12, 2023

SELL
$38.16 - $48.86 $1.22 Million - $1.57 Million
-32,046 Reduced 29.44%
76,822 $3.72 Million
Q4 2022

Feb 08, 2023

BUY
$33.53 - $54.79 $2.62 Million - $4.28 Million
78,107 Added 253.92%
108,868 $4.16 Million
Q3 2022

Nov 10, 2022

SELL
$41.85 - $53.85 $1.13 Million - $1.46 Million
-27,031 Reduced 46.77%
30,761 $1.54 Million
Q2 2022

Aug 10, 2022

SELL
$25.6 - $45.23 $2.15 Million - $3.81 Million
-84,177 Reduced 59.29%
57,792 $2.32 Million
Q1 2022

May 16, 2022

BUY
$33.33 - $44.6 $409,859 - $548,446
12,297 Added 9.48%
141,969 $5.3 Million
Q4 2021

Feb 14, 2022

BUY
$35.36 - $41.86 $2.36 Million - $2.8 Million
66,850 Added 106.41%
129,672 $5.16 Million
Q3 2021

Nov 15, 2021

BUY
$37.01 - $44.74 $2.32 Million - $2.81 Million
62,729 Added 67450.54%
62,822 $2.34 Million
Q2 2021

Aug 13, 2021

SELL
$37.95 - $49.37 $1.25 Million - $1.62 Million
-32,879 Reduced 99.72%
93 $4,000
Q1 2021

May 12, 2021

BUY
$46.8 - $68.92 $1.53 Million - $2.25 Million
32,588 Added 8486.46%
32,972 $1.56 Million
Q4 2020

Feb 11, 2021

BUY
$47.96 - $67.64 $4,316 - $6,087
90 Added 30.61%
384 $23,000
Q3 2020

Nov 12, 2020

SELL
$45.41 - $57.07 $216,560 - $272,166
-4,769 Reduced 94.19%
294 $14,000
Q2 2020

Jul 31, 2020

SELL
$42.56 - $54.98 $2.84 Million - $3.67 Million
-66,826 Reduced 92.96%
5,063 $257,000
Q1 2020

May 01, 2020

BUY
$32.37 - $59.36 $457,711 - $839,350
14,140 Added 24.49%
71,889 $3.21 Million
Q4 2019

Feb 14, 2020

SELL
$32.22 - $50.07 $929,772 - $1.44 Million
-28,857 Reduced 33.32%
57,749 $2.77 Million
Q3 2019

Nov 14, 2019

BUY
$33.82 - $48.17 $2.62 Million - $3.73 Million
77,339 Added 834.56%
86,606 $2.93 Million
Q2 2019

Aug 14, 2019

BUY
$35.42 - $45.0 $14,557 - $18,495
411 Added 4.64%
9,267 $417,000
Q1 2019

May 14, 2019

SELL
$28.09 - $39.49 $2.09 Million - $2.94 Million
-74,541 Reduced 89.38%
8,856 $334,000
Q4 2018

Feb 14, 2019

BUY
$29.83 - $46.51 $1.59 Million - $2.48 Million
53,298 Added 177.08%
83,397 $2.86 Million
Q3 2018

Nov 14, 2018

BUY
$33.9 - $47.77 $613,183 - $864,063
18,088 Added 150.6%
30,099 $1.42 Million
Q2 2018

Aug 14, 2018

BUY
$25.7 - $47.88 $44,024 - $82,018
1,713 Added 16.63%
12,011 $405,000
Q1 2018

May 15, 2018

SELL
$17.46 - $32.59 $1.14 Million - $2.14 Million
-65,565 Reduced 86.43%
10,298 $279,000
Q4 2017

Feb 14, 2018

BUY
$15.14 - $20.89 $183,951 - $253,813
12,150 Added 19.07%
75,863 $1.27 Million
Q3 2017

Nov 14, 2017

BUY
$16.81 - $21.61 $609,816 - $783,945
36,277 Added 132.22%
63,713 $1.28 Million
Q2 2017

Aug 14, 2017

BUY
N/A
3,123 Added 12.84%
27,436 $503,000
Q1 2017

Nov 14, 2017

BUY
N/A
24,313
24,313 $239,000

Others Institutions Holding PTCT

About PTC THERAPEUTICS, INC.


  • Ticker PTCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,541,000
  • Market Cap $2.81B
  • Description
  • PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on...
More about PTCT
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.